Key Takeaways
- Soft quarter, structural bets intact: Sales grew 7% but volumes fell 5%, EBITDA dropped 15%, and PAT declined 25%. The damage was concentrated: India Household Insecticide missed badly, Indonesia margins collapsed, while the rest of India performed well.
- A deliberate margin trade is underway: Advertising spend jumped ~50% as part of a philosophical, multi-year shift to invest in category development. Management will not cut media to defend a margin target, betting cost savings and volume leverage will close the gap over time.
- Soap volumes are turning, and that matters: With palm prices cooling, GCPL led on price drops and is already seeing volumes return. The thesis is that consumption never fell, only trade pipelines did, so a compensatory volume bounce is expected soon.
- Household Insecticide is the open wound: A weak Q2, blamed partly on delayed monsoons, exposed the deeper problem: the market leader still cannot crack premiumization. Management is unsure how much is seasonality versus a need to change course.
- What to watch next quarter: Whether Household Insecticide volumes normalize in H2 as promised, whether Indonesia really hits near-flat growth in Q3, and whether the soap volume recovery is strong enough to offset the ad-spend drag on margins.
Household Insecticide: The Core Problem
- Q2 was a clear miss: India Household Insecticide was the only part of the portfolio that sold below expectations, dragging the three-year CAGR from 4% in Q1 to 1% in Q2. The weakness was concentrated in August-end and September, with delayed monsoons spreading into October as a partial explanation.
- Seasonality or strategy? Management cannot yet separate the seasonal impact from the need for a course correction on its interventions. Q1 had been encouraging, making the Q2 reversal harder to read.
- The premiumization challenge persists: The primary goal is not to win share but to premiumize the category and grow it faster. Distribution is not the bottleneck, unlike in Air Care, so the solution lies elsewhere.
- Market share directionally down: Over three to four years, GCPL has lost some share, largely due to the emergence of incense sticks as a format. Management declined to share current share specifics, saying only that it has "largely kept market share."
- H2 bet on softer comparators: With seasonality shifting and comparators easing, volumes should return to normative levels in H2. Management will review strategy after seeing how H2 plays out.
Sitapati: "Our challenge in Household Insecticide, Abneesh is not to win share, our primary challenge given the fact that we are market leader is to premiumize this category and grow it faster."
The Advertising Bet: Philosophy Over Quarters
- A structural step-up, not a phase: Advertising spend rose nearly 50% in Q2, and management was explicit that this is a philosophical, multi-year shift to invest what the portfolio deserves, not a few-quarters tactical move.
- The offset plan: The objective is to cover as much of the increased working media as possible through cost savings in areas apart from COGS and working media, with significant potential identified in cost-to-serve. Any remaining gap is to be covered by volume leverage.
- No margin target will stop it: Management will not cut media to defend a target EBITDA margin, nor will it stop saving costs even if a margin target is met. The demand environment is not the relevant variable for these investment decisions.
- India above-the-line grew 52%: The India business absorbed a 52% increase in above-the-line spend, which drove the 5% EBITDA decline there. Ex-Household Insecticides, the rest of India performed very well.
Sitapati: "This is certainly not something we are going to do for a few quarters, it's certainly more philosophical, in terms of what our portfolio deserves, and what we should do for it."
Soaps: The Volume Recovery Thesis
- Pricing philosophy drove the trade: When palm prices rose, GCPL did not pass on full inflation, knowing prices would come down. When they did fall in Q2, GCPL passed on the drop quickly despite sitting on high-cost inventory, prioritizing consumers over near-term gross margins.
- Volumes are already responding: With soap prices cooling and GCPL taking the lead on price drops, volumes are coming back. The underlying belief is that consumption never fell, only trade pipelines compressed over four quarters of hyperinflation.
- Compensatory upside expected soon: A volume bounce is expected to compensate for fallen volumes, assuming consumption held. Long-term, category growth is pegged at 3–3.5% with GCPL aiming for 100–150 bps above that, and margins should return close to normative levels.
Sitapati: "When prices went up, we did not pass on the full inflation to consumers because we knew that prices would come down. When prices came down... we passed it on quickly because our underlying principle on this is to be on the side of consumers."
International: Indonesia Bleeds, Africa Invests
| Market | Trend | Commentary |
|---|---|---|
| Indonesia | ▼ Sharp decline | Sales –8%, gross margins –14%, EBITDA –41%. Ex-Saniter growth was 12%, so the base effect from Saniter inventory reduction is the dominant drag. High-cost inventory consumption and scale deleverage added to the margin hit. |
| GUAM | ▬ Investing | Good operating quarter with 15% growth, but EBITDA fell 12% on a 77% ATL increase. Margins down ~270 bps: half from media, half from input costs and sharp currency depreciation in some markets. |
| Africa | ▬ Mixed | 15% sales growth, 8% gross margin expansion, but EBITDA declined 12% as ATL rose 77%. Severe currency depreciation pushed up forex and interest costs. |
- Indonesia margin ambition intact: Management wants to reach early-20s margins while continuing to invest in marketing. High-cost commodity impact will start flattening, and scale deleverage will lighten but not fully reverse until Q4.
- Africa margin target unchanged: The high-teens margin target remains, to be reached through scale, a considerable cost-saving program, and potential changes to the operating model. Direct retail distribution expansion is yielding rich results in Household Insecticide and Hair Care.
- Forex losses may rise near-term: In Africa, the quantum of forex losses could move up in coming quarters before easing once currencies stabilize.
- Indonesia general trade a structural problem: Management is working to shift general trade salience from 30 odd to 50 odd, a structural fix that will take time.
Sitapati: "I hope that Q3 will come to near flat in Indonesia and Q4 onward, we should see very high growth."
Portfolio Bright Spots
- Air Care exploded: Growth was driven by investing in one SKU, Aer Matic, with a massive increase in both distribution and media. This is the playbook management wants to replicate: pick a SKU, push distribution, back it with media.
- Non-HI India portfolio grew strongly: The rest of India pulled overall growth to 8% despite a difficult Household Insecticides quarter, which is a large component of the business.
- SKU rationalization is real: India reduced SKUs by 25% in six months; GUAM cut SKUs by one-third in a year. Inventory days fell from 60 to 51. Operating cash flow doubled, driven by working capital simplification.
- Africa FMCG growth: Fast growth in Household Insecticide and Hair Care, driven by direct retail distribution expansion, an approach that is working where the distribution problem is still unsolved.
Margins: The Walk and the Philosophy
- The Q2 margin walk: Gross margins grew 3% after four quarters of decline, a positive signal. But EBITDA fell 15%, led almost entirely by the ~50% increase in advertising spends. PAT fell 25%, additionally hit by a VAT Amnesty Scheme settlement and currency volatility.
- Gross margin could have been higher: In India, GCPL priced for replacement cost despite sitting on high-cost palm inventory, deliberately sacrificing margin to stay on the side of consumers and support volume recovery.
- Directionally up from here: Overall gross margins should rise sequentially and YoY in coming quarters, though management is unsure they will return to the +800–900 bps level of eight to nine quarters ago.
- No specific margin target: Management declined to name a "right" margin, arguing it is better not to target one. The definition of profitable growth is sales growth backed by margin expansion, not a fixed number.
Sitapati: "I don't think we should stop at either cut on media, because we are not achieving a target EBITDA margin or stop at an EBITDA margin, even if there are more cost to be saved."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY23 sales growth | Double-digit sales growth | FY23 full year |
| FY23 volume growth | Low single-digit volume growth | FY23 full year |
| Indonesia growth trajectory | Near-flat in Q3, very high growth from Q4 onward | Q3 FY23 / Q4 FY23 |
| Indonesia margins | Ambition to reach early-20s margins while continuing marketing investments | No date (investment mode continues) |
| Africa margins | Reach high-teens margin via scale, cost savings, operating model changes | No date (target "very much intact") |
| Household Insecticide volumes | Return to normative level in H2 on softer comparators and seasonality shift | H2 FY23 |
| Soap volumes | Compensatory upside expected "pretty soon" to compensate for fallen volumes | Near-term (no specific quarter) |
| Soap gross margins | Return close to FY21 normative levels | No date |
| Overall gross margins | Rise sequentially and YoY in coming quarters | Coming quarters |
| Advertising spend | Increase from current levels over next four to five years | 4–5 year horizon |
| EBITDA margin | No massive declines versus the past; media increase offset by cost savings and volume leverage | Ongoing |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Sales growth | 7%, three-year CAGR of 9% |
| Volume growth | -5%, three-year CAGR of +1% |
| Gross margin growth | +3%, after four quarters of decline |
| Advertising spend growth | ~50% increase |
| EBITDA growth | -15% |
| PAT growth | -25%, led by VAT Amnesty Scheme settlement and currency volatility |
| Operating cash flow | Doubled, driven by working capital simplification |
| India sales growth | 8%, three-year CAGR of 1% vs 4% in Q1 |
| India gross margin growth | 7% |
| India ATL growth | 52% |
| India EBITDA growth | -5% |
| GUAM sales growth | 15% |
| GUAM gross margin growth | 8% |
| GUAM ATL growth | 77% |
| GUAM EBITDA growth | -12% |
| Indonesia sales growth | -8%, ex-Saniter growth of 12% |
| Indonesia gross margin growth | -14% |
| Indonesia EBITDA growth | -41% |
| Indonesia margin decline | 930 bps, 150 bps from upfront working media investment |
| Africa margin decline | ~270 bps, half from upfront media investments, half from input cost and currency depreciation |
| ATL growth | 46% |
| Working media growth | 70% |
| India SKU reduction | 25% in the last six months |
| GUAM SKU reduction | One-third in the last one year |
| Inventory days | 51 days as at September '22, down from 60 days as at September '21 |
| Cost-to-serve reduction | 30 bps in Q2 FY22, despite high inflation |
| Soaps long-term volume CAGR | 3% to 3.5% for the category, GCPL expected at 4% to 4.5% |
| Soaps market share gain trajectory | 50 to 60 bps per year for the last decade |
| Margin expansion target | 150 to 200 bps over a period of time |